Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
By Connor Hart
Vertex Pharmaceuticals said a new drug submission for its treatment for moderate to severe acute pain has been accepted for review by Health Canada.
The biotechnology company said Thursday that the therapy, suzetrigine, if approved could be the first new class of medicine in Canada to treat acute pain in over 20 years.
Suzetrigine inhibits NaV1.8 currents, a voltage-gated sodium channel that has garnered attention because of its pivotal role in pain signaling. The treatment isn't an opioid or a nonsteroidal anti-inflammatory drug, it represents a new class of oral pain medicine, Vertex said.
"Today's acceptance of our NDS for suzetrigine represents an important step in our mission to transform pain management in Canada," said Michael Siauw, general manager of Vertex Canada.
Suzetrigine was approved in January 2025 by the Food and Drug Administration, with the application receiving breakthrough therapy, fast track and priority review designations, Vertex said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
May 21, 2026 13:43 ET (17:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States